RA
Robert Adelman
OtherActiveManaging Director at venBio
38
Investments
0
Exits
—
AUM
0.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Robert Adelman.
Investment Thesis & Strategy
Robert Adelman, as Managing Director at venBio, invests in various stages of biotech and pharmaceutical companies, seeking to support innovative therapeutics and technologies.
Investment Activity
Deals per year over the last 2 years
3
20191
2020Portfolio Companies
Selected investments from their portfolio of 38 companies
A
Arrakis Therapeutics
Biotech · Series B, 0
N
NFlection Therapeutics
Biotech · Seed, 0
N
Neurogastrx
Biotech · Seed, 0
P
Pharvaris
Biotech · Series B, 0
I
INBRACE
Healthcare · Series A, 0
C
Cidara Therapeutics
Biotech · Series B, 0
F
Fog Pharmaceuticals
Biotech · Seed, 0
A
Aragon Pharmaceuticals
Biotech · Series B, 0
R
RayzeBio
Other · , 2020
V
Ventyx Biosciences
Other · , 2019
E
Elevation Oncology
Biotech · Seed, 2019
A
Artiva Biotherapeutics
Biotech · Series A, 2019
Frequently Asked Questions
Robert Adelman focuses on Series B stage investments.
Related Investors
Bill Coughran
San Francisco, United States · 104 deals
Dave Lambert
San Francisco, United States · 101 deals
Arun Mathew
San Francisco, United States · 99 deals
Ash Rust
San Francisco, United States · 96 deals
Alex Tran
San Francisco, United States · 95 deals
Randy Williams
San Francisco, United States · 95 deals